On Tuesday, Shares of MiMedx Group Inc (NASDAQ:MDXG), lost -14.23% to $8.44.
MiMedx Group, declared its record revenue results for the third quarter of 2015, its guidance for the fourth quarter of 2015, and that the Company has secured a $50 million Senior Secured Credit Facility.
Third Quarter 2015 Preliminary Highlights are:
- Q3 is 16th successive quarter of meeting or surpassing revenue guidance
- 2015 nine-month revenue of $135.5 million raised by 72% over same period of 2014
- Q3 Revenue of $49 million raised by 46% over Q3 2014
- $49 million revenue is at upper end of $47 to $50 million Q3 guidance range
- The 15th successive quarter of positive Adjusted EBITDA
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix.
Shares of 3D Systems Corporation (NYSE:DDD), declined -2.85% to $12.93, during its last trading session.
3D Systems, declared the introduction of advanced cardiology training modules for the ANGIO Mentor(TM) VR simulator, together with a cardiovascular anatomical model product line that allows visualization of complex cardiovascular anatomy.
Over the last decade, developments in interventional cardiology have allowed more patients to be treated using minimally invasive Percutaneous Coronary Intervention (PCI) procedures. In order to provide practiced cardiologists with training for the most up-to-date and complex treatment techniques with PCI, 3DS has developed advanced training scenarios for Coronary CTO (Chronic Total Occlusion) and Coronary Bifurcation cases for use with its ANGIO Mentor endovascular training simulator. Watch a video of an ANGIO Mentor Advanced Coronary Interventions Simulation here.
In addition, the company’s patient-specific cardiovascular anatomical models can be used to enhance planning in complex procedures. 3DS’ cardiovascular anatomical modeling service uses patient-specific imaging data from CT or MR scans to design a patient-specific model that can be 3D printed in a variety of materials. These models are suitable for use as pre-surgical planning tools, educational resources, and benchtop fixtures for testing of instruments and implants.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries.
Finally, Phillips 66 (NYSE:PSX), ended its last trade with -2.04% loss, and closed at $82.16.
Phillips 66 (PSX), declares its 2016 capital budget of $3.6 billion, not taking into account Phillips 66 Partners’ capital program. The board of directors of Phillips 66 also approved a $2.0 billion improvement to the company’s share repurchase program.
“The 2016 capital budget will fund Midstream growth and enhance returns in Refining,” said chairman and CEO Greg Garland. “Cash from operating activities, our MLP and a strong balance sheet allow us to fund business growth while returning capital to shareholders.”
Not Taking Into Account Phillips 66 Partners’ capital spending, Phillips 66 plans to invest $2.0 billion in its Midstream business lines. In Natural Gas Liquids (NGL), the company continues construction of the 4.4 million-barrel-per-month Freeport LPG Export Terminal on the U.S. Gulf Coast, with completion predictable in the second half of 2016. In addition, the budget comprises spending associated with expansion of the Sweeny NGL midstream hub.
Phillips 66 operates as an energy manufacturing and logistics company. It operates through four segments: Midstream, Chemicals, Refining, and Marketing and Specialties (M&S).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.